Common dermatologic conditions

Medical Clinics of North America

Volumn 98, Issue 3, 2014, Pages 445-485

  Vary, Jay C ^a   O'Connor, Kim M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Div of General Internal Medicine   (United States)

Author keywords

Acne; Alopecia; Facial rashes; Intertriginous rashes; Leg rashes

Indexed keywords

CORTICOSTEROID DERIVATIVE; TOPICAL AGENT;

ACNE VULGARIS; ALOPECIA AREATA; ANTIMICROBIAL THERAPY; CANDIDIASIS; CELLULITIS; COMEDO; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DERMATITIS; DERMATOPHYTOSIS; ERYSIPELAS; ERYTHRASMA; FEMALE PATTERN HAIR LOSS; HAIR LOSS; HUMAN; INTERTRIGINOUS RASH; INVERSE PSORIASIS; MALE TYPE ALOPECIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ONSET AGE; PERIORAL DERMATITIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS; SKIN DISEASE; STASIS DERMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC THERAPY; TELOGEN EFFLUVIUM; TOPICAL TREATMENT;

ACNE; ALOPECIA; FACIAL RASHES; INTERTRIGINOUS RASHES; LEG RASHES;

DIAGNOSIS, DIFFERENTIAL; HUMANS; SKIN; SKIN DISEASES;

EID: 84898919070     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.01.005     Document Type: Review

References (84)

1. Fien S., Berman B., Magrane B. Skin disease in a primary care practice. Skinmed 2005, 4(6):350-353.
2. Lowell B.A., Froelich C.W., Federman D.G., et al. Dermatology in primary care: prevalence and patient disposition. JAm Acad Dermatol 2001, 45(2):250-255.
3. Hamilton J.B. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951, 53(3):708-728.
4. Norwood O.T. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001, 27(1):53-54.
5. Futterweit W., Dunaif A., Yeh H.C., et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. JAm Acad Dermatol 1988, 19(5 Pt 1):831-836.
6. Karrer-Voegeli S., Rey F., Reymond M.J., et al. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore) 2009, 88(1):32-45.
7. Ellis J.A., Sinclair R., Harrap S.B. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002, 4(22):1-11.
8. Camacho-Martinez F.M. Hair loss in women. Semin Cutan Med Surg 2009, 28(1):19-32.
9. Arias-Santiago S., Gutierrez-Salmeron M.T., Castellote-Caballero L., et al. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. JAm Acad Dermatol 2010, 63(3):420-429.
10. Olsen E.A., Whiting D., Bergfeld W., et al. Amulticenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. JAm Acad Dermatol 2007, 57(5):767-774.
11. Lucky A.W., Piacquadio D.J., Ditre C.M., et al. Arandomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. JAm Acad Dermatol 2004, 50(4):541-553.
12. Blume-Peytavi U., Hillmann K., Dietz E., et al. Arandomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. JAm Acad Dermatol 2011, 65(6):1126-1134.e2.
13. Kaufman K.D., Olsen E.A., Whiting D., et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. JAm Acad Dermatol 1998, 39(4 Pt 1):578-589.
14. Mella J.M., Perret M.C., Manzotti M., et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010, 146(10):1141-1150.
15. Irwig M.S., Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. JSex Med 2011, 8(6):1747-1753.
16. Redman M.W., Tangen C.M., Goodman P.J., et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008, 1(3):174-181.
17. Eun H.C., Kwon O.S., Yeon J.H., et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. JAm Acad Dermatol 2010, 63(2):252-258.
18. Rathnayake D., Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010, 28(3):611-618.
19. van Zuuren E.J., Fedorowicz Z., Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol 2012, 167(5):995-1010.
20. Mackenzie I.S., Macdonald T.M., Thompson A., et al. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 2012, 345:e4447.
21. McMichael A.J., Pearce D.J., Wasserman D., et al. Alopecia in the United States: outpatient utilization and common prescribing patterns. JAm Acad Dermatol 2007, 57(Suppl 2):S49-S51.
22. Gilhar A., Etzioni A., Paus R. Alopecia areata. NEngl J Med 2012, 366(16):1515-1525.
23. Alkhalifah A., Alsantali A., Wang E., et al. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. JAm Acad Dermatol 2010, 62(2):177-188. [quiz: 189-90].
24. Goh C., Finkel M., Christos P.J., et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. JEur Acad Dermatol Venereol 2006, 20(9):1055-1060.
25. Messenger A.G., McKillop J., Farrant P., et al. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol 2012, 166(5):916-926.
26. Whiting D.A. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. JAm Acad Dermatol 1996, 35(6):899-906.
27. Kligman A.M. Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch Dermatol 1961, 83:175-198.
28. Shrivastava S.B. Diffuse hair loss in an adult female: approach to diagnosis and management. Indian J Dermatol Venereol Leprol 2009, 75(1):20-27. [quiz: 27-8].
29. Harrison S., Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002, 27(5). 389-5.
30. O'Connor K., Paauw D. Erysipelas: rare but important cause of malar rash. Am J Med 2010, 123(5):414-416.
31. Stathakis V., Kilkenny M., Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol 1997, 38(3):115-123.
32. Thiboutot D., Gollnick H., Bettoli V., et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. JAm Acad Dermatol 2009, 60(Suppl 5):S1-S50.
33. Williams H.C., Dellavalle R.P., Garner S. Acne vulgaris. Lancet 2012, 379(9813):361-372.
34. Gamble R., Dunn J., Dawson A., et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. Am J Clin Dermatol 2012, 13(3):141-152.
35. Simonart T. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol 2012, 13(6):357-364.
36. Mays R.M., Gordon R.A., Wilson J.M., et al. New antibiotic therapies for acne and rosacea. Dermatol Ther 2012, 25(1):23-37.
37. Tan J. Dapsone 5% gel: a new option in topical therapy for acne. Skin Therapy Lett 2012, 17(8):1-3.
38. Gallo R., Drago F., Paolino S., et al. Rosacea treatments: what's new and what's on the horizon?. Am J Clin Dermatol 2010, 11(5):299-303.
39. May D., Kelsberg G., Safranek S. Clinical inquiries. What is the most effective treatment for acne rosacea?. JFam Pract 2011, 60(2). 108a-100c.
40. Altinyazar H.C., Koca R., Tekin N.S., et al. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005, 44(3):252-255.
41. Fowler J.F. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. JDrugs Dermatol 2007, 6(6):641-645.
42. Sanchez J., Somolinos A.L., Almodovar P.I., et al. Arandomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. JAm Acad Dermatol 2005, 53(5):791-797.
43. Bencini P.L., Tourlaki A., De Giorgi V., et al. Laser use for cutaneous vascular alterations of cosmetic interest. Dermatol Ther 2012, 25(4):340-351.
44. Lipozencic J., Ljubojevic S. Perioral dermatitis. Clin Dermatol 2011, 29(2):157-161.
45. Hafeez Z.H. Perioral dermatitis: an update. Int J Dermatol 2003, 42(7):514-517.
46. Oppel T., Pavicic T., Kamann S., et al. Pimecrolimus cream (1%) efficacy in perioral dermatitis-results of a randomized, double-blind, vehicle-controlled study in 40 patients. JEur Acad Dermatol Venereol 2007, 21(9):1175-1180.
47. Schwarz T., Kreiselmaier I., Bieber T., et al. Arandomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. JAm Acad Dermatol 2008, 59(1):34-40.
48. Weber K., Thurmay R., Meisinger A. Atopical erythromycin preparation and oral tetracycline for the treatment of perioral dermatitis: a placebo controlled trial. JDermatol Treat 1993, 4:57.
49. Veien N.K., Munkvad J.M., Nielsen A.O., et al. Topical metronidazole in the treatment of perioral dermatitis. JAm Acad Dermatol 1991, 24(2 Pt 1):258-260.
50. Soeprono F.F., Schinella R.A., Cockerell C.J., et al. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. JAm Acad Dermatol 1986, 14(2 Pt 1):242-248.
51. Berger R.S., Stoner M.F., Hobbs E.R., et al. Cutaneous manifestations of early human immunodeficiency virus exposure. JAm Acad Dermatol 1988, 19(2 Pt 1):298-303.
52. Wolf R., Oumeish O.Y., Parish L.C. Intertriginous eruption. Clin Dermatol 2011, 29(2):173-179.
53. Janniger C.K., Schwartz R.A., Szepietowski J.C., et al. Intertrigo and common secondary skin infections. Am Fam Physician 2005, 72(5):833-838.
54. Cramer D.W., Liberman R.F., Titus-Ernstoff L., et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999, 81(3):351-356.
55. Phillips R.M., Rosen T. Topical antifungal agents. Comprehensive dermatologic drug therapy 2007, 547-568. Saunders Elsevier, Philadelphia. 2nd edition. S.E. Wolverton (Ed.).
56. Holdiness M.R. Management of cutaneous erythrasma. Drugs 2002, 62(8):1131-1141.
57. Clayton Y.M., Hay R.J., McGibbon D.H., et al. Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol 1982, 7(5):543-549.
58. Pitcher D.G., Noble W.C., Seville R.H. Treatment of erythrasma with miconazole. Clin Exp Dermatol 1979, 4(4):453-456.
59. Ramelet A.A., Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica 1987, 175(6):293-295.
60. Grigoriu D., Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica 1983, 166(Suppl 1):8-13.
61. Avci O., Tanyildizi T., Kusku E. Acomparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. JDermatolog Treat 2013, 24(1):70-74.
62. Seville R.H., Somerville D.A. The treatment of erythrasma in a hospital for the mentally subnormal. Br J Dermatol 1970, 82(5):502-506.
63. Weigle N., McBane S. Psoriasis. Am Fam Physician 2013, 87(9):626-633.
64. David C.V., Chira S., Eells S.J., et al. Diagnostic accuracy in patients admitted to hospitals with cellulitis. Dermatol Online J 2011, 17(3):1.
65. Hirschmann J.V., Raugi G.J. Lower limb cellulitis and its mimics: part II. Conditions that simulate lower limb cellulitis. JAm Acad Dermatol 2012, 67(2):177.e1-177.e9. [quiz: 185-6].
66. Hirschmann J.V., Raugi G.J. Lower limb cellulitis and its mimics: part I. Lower limb cellulitis. JAm Acad Dermatol 2012, 67(2):163.e1-163.e12. [quiz: 175-6].
67. Roujeau J.C., Sigurgeirsson B., Korting H.C., et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004, 209(4):301-307.
68. Semel J.D., Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996, 23(5):1162-1164.
69. McNamara D.R., Tleyjeh I.M., Berbari E.F., et al. Incidence of lower-extremity cellulitis: a population-based study in Olmsted county, Minnesota. Mayo Clin Proc 2007, 82(7):817-821.
70. Celsus A. De Medicina. Circa 50 AD.
71. Jeng A., Beheshti M., Li J., et al. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 2010, 89(4):217-226.
72. Bergkvist P.I., Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis 1997, 29(4):377-382.
73. Pierard G.E., Quatresooz P. What do you mean by eczema craquele?. Dermatology 2007, 215(1):3-4.
74. Bhushan M., Cox N.H., Chalmers R.J. Eczema craquele resulting from acute oedema: a report of seven cases. Br J Dermatol 2001, 145(2):355-357.
75. O'Meara S., Cullum N., Nelson E.A., et al. Compression for venous leg ulcers. Cochrane Database Syst Rev 2012, (11). CD000265.
76. Shingler S., Robertson L., Boghossian S., et al. Compression stockings for the initial treatment of varicose veins in patients without venous ulceration. Cochrane Database Syst Rev 2011, (11). CD008819.
77. Partsch H., Flour M., Smith P.C., et al. Indications for compression therapy in venous and lymphatic disease consensus based on experimental data and scientific evidence. Under the auspices of the IUP. Int Angiol 2008, 27(3):193-219.
78. Cornu-Thenard A., Boivin P., Carpentier P.H., et al. Superimposed elastic stockings: pressure measurements. Dermatol Surg 2007, 33(3):269-275. [discussion: 275].
79. Smart V., Alavi A., Coutts P., et al. Contact allergens in persons with leg ulcers: a Canadian study in contact sensitization. Int J Low Extrem Wounds 2008, 7(3):120-125.
80. Wells P.S., Hirsh J., Anderson D.R., et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995, 345(8961):1326-1330.
81. Wells P.S., Hirsh J., Anderson D.R., et al. Asimple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. JIntern Med 1998, 243(1):15-23.
82. Chowdhury M.M. Dermatological pharmacology: topical agents. Medicine 2004, 32(12):16-17.
83. Finlay A.Y., Edwards P.H., Harding K.G. "Fingertip unit" in dermatology. Lancet 1989, 2(8655):155.
84. Long C.C., Finlay A.Y. The finger-tip unit-a new practical measure. Clin Exp Dermatol 1991, 16(6):444-447.